Celixir plc
- Home
- Companies
- Celixir plc
- Products
- Celixir Heartcel - Immunomodulatory ...
Celixir Heartcel - Immunomodulatory Progenitor Cells
FromCelixir plc
PHASE 2 : Our first investigational cardiac regenerative medicine consists of iMP cells. iMP cells are designed to treat patients with ischaemic heart disease – ischaemic cardiomyopathy – undergoing coronary artery bypass graft (CABG). They are injected around cardiac scar tissue via a single application during bypass surgery.
Most popular related searches
coronary artery bypass graft
coronary artery bypass
coronary arterial
arterial bypass
cardiac disease
bypass surgery
regenerative medicine
coronary bypass graft
artery graft
coronary bypass
STATUS:
We have successfully completed European Phase 2 trials using iMP cells as a cardiac-specific cellular medicine. Additional trials are set to begin in 2018. iMP cells have been designated as an advanced therapeutic medicinal product by the European Medicines Agency. A Phase 2 trial in Kawasaki disease is also planned.